Data Published Online in The Journal of Clinical Psychiatry Show Long-Term Benefit of Non-Drug NeuroStar TMS Therapy® in Patients with Treatment Resistant Depression
Largest clinical study evaluating durability of treatment with the NeuroStar shows depression patients maintained remission through 52 weeks
MALVERN, Pa., Sept. 16, 2014 /PRNewswire/ — Neuronetics, Inc., today announced that results of a study designed to assess the long-term effectiveness of NeuroStar TMS Therapy in adult patients with Major Depressive Disorder (MDD) who have failed to benefit from prior treatment with antidepressant medications, were published online in The Journal of Clinical Psychiatry. The study found that TMS treatment with the NeuroStar TMS Therapy System induced statistically and clinically meaningful response and remission in patients with treatment resistant MDD during the acute phase of therapy, which were maintained through one year of follow-up. At the end of acute treatment, 62 percent of patients achieved symptomatic improvement while 41 percent reported complete remission. At 12 months, 68 percent of patients achieved symptomatic improvement while 45 percent reported complete remission. Maintenance of benefit was observed under a pragmatic regimen of continued antidepressant medication and TMS reintroduction for symptom recurrence.